CVE-2023-42666: Dexma Dexgate

Medium severity, CVSS 5.3. EPSS: 0.5% chance of exploitation in the next 30 days.

The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which may allow an attacker to create malicious requests for obtaining the information of the version about the web server used.

Affected products

• Dexma Dexgate: version 20130114 only

Published 2023-10-19. Last modified 2026-06-17.